Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02743819 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
A Phase 2 study of Melanoma, sponsored by University of Chicago.
- Active
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 10
- Study locations
NCT02743819 is a Phase 2 study of Melanoma that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 70 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 5 states.
The verdict
NCT02743819, a Phase 2 study of Melanoma, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 10
- Study locations
Study Summary
Phase II study evaluating the benefit of the combination of anti-PD1 (pembrolizumab) and anti-CTLA4 (ipilimumab) antibodies in advanced melanoma. The study will determine the response rate of the combination and evaluate other clinical parameters such as progression-free survival and safety of the combination following anti-PD1/L1 antibody. The study will also provide the opportunity to investigate blood or tumor based factors that may predict response to anti-PD1 antibody in combination with anti-CTLA4.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Ipilimumab
Study Locations (10)
Illinois
- University of Chicago - Chicago
- Decatur Memorial Hospital - Decatur
- NorthShore University HealthSystem - Evanston
- Oncology Specialists S.C. - Park Ridge
- Illinois Cancer Care - Peoria
Florida
- Mount Sinai Medical Center of Florida - Miami Beach
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Alabama
- University of South Alabama - Mobile
Indiana
- Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne
Virginia
- Virginia Commonwealth University/ Massey Cancer Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-06-28 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02743819
The ClinicalTrials.gov registry entry for NCT02743819 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (90% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02743819 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT02743819 about?
NCT02743819 is a clinical study titled "Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma". Phase II study evaluating the benefit of the combination of anti-PD1 (pembrolizumab) and anti-CTLA4 (ipilimumab) antibodies in advanced melanoma. The study will determine the response rate of the combination and evaluate other clinical parameters such as progression-free survival and safety of the c...
What is the current status of trial NCT02743819?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2016-06-28. Estimated completion is 2026-06.
What conditions does trial NCT02743819 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT02743819?
The interventions under investigation include: Pembrolizumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT02743819?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02743819 being conducted?
This trial has 10 study locations across Alabama, Florida, Illinois, Indiana, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.